Observational studyJournal of neurology2026
Long-term clinical and radiological trajectories in ANO5-related myopathies highlight muscle MRI as a predictor of disease progression.
Observational study in Journal of neurology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors.
Funding
Abstract
BACKGROUND AND
objectivesAnoctamin-5 gene (ANO5)-related myopathies are clinically heterogeneous, and predictors of progression remain poorly defined. This study aims to characterize their long-term clinical and radiological evolution and identify factors influencing disease severity.
methodsWe conducted a retrospective observational study of patients with anoctaminopathies in the Valencian Community (Spain). Demographic, clinical, genetic, ancillary tests, and serial muscle MRI data were analyzed using univariate and Bayesian multivariate models.
resultsThirty patients (21 males) from 23 families were included. Median disease duration was 13.5 years, and follow-up was 7 years (range 3-31). Median age at first assessment was 43.5 years (range 9-78). Most patients presented with pseudometabolic myopathy (47%) or asymptomatic hyperCKemia (37%), while 16% had LGMD-R12/MMD3. Nearly one-third of symptomatic patients had a documented asymptomatic hyperCKemia period (median 5.5 years). At last assessment, 27% had LGMD-R12/MMD3, 43% had pseudometabolic myopathy, and 30% remained asymptomatic. The most frequent variants were c.191dupA (35%) and c.692G > T (22%). CK levels, biopsy and EMG findings did not distinguish phenotypes. Baseline MRI revealed fat infiltration and STIR hyperintensities in most patients across all phenotypes. Muscle involvement progressed in 95% of serial scans. STIR hyperintensities preceded fat replacement in approximately 50% of muscles. More severe phenotypes correlated with older age, loss-of-function variants, and higher MRI T1 scores. Estimated prevalence was 1.8/100,000 in our region. DISCUSSION: ANO5-related myopathies show progressive muscle involvement regardless of phenotype. Muscle MRI analysis provides valuable outcome measures for monitoring and future clinical trials, with STIR hyperintensities as a sensitive biomarker of disease activity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.